New Norwegian heart sensor better than today’s hospital equipment for detecting atrial fibrillation

LILLESAND, Norway, November 10, 2021 / PRNewswire / – The innovative ECG247 heart rate sensor, which was developed and manufactured by Appsens AS in Norway, is proving to be better than the equipment most hospitals and cardiologists around the world use to detect heart rhythm disturbances, according to a new study published in the popular Journal of Healthcare Engineering. ECG247 makes it easier to detect severe heart rhythm disturbances before they cause symptoms, says project manager Elisabeth ramsdal from Appsens.

Doctor of medicine and doctoral student at Sorlandet Edvard L Sandberg Hospital in collaboration with researchers from for example, University of Oslo Hospital and St. Olav Hospital compared the ECG247 heart sensor with standard hospital equipment to detect abnormal heart rhythms (called a Holter exam or long-term ECG). In the study, the two systems were used simultaneously in 150 patients for several days. The ECG247 detected arrhythmias comparable to those of Holter technology, but had significantly fewer erroneous test results (fewer false positives). Additionally, the study showed that the ECG247 sensor is much easier and more comfortable to use than regular Holter equipment.

The ECG247 cardiac sensor was developed in collaboration with researchers from Sorlandet Hospital and Agder University. The system consists of a small, reusable sensor that is attached to the skin over the breastbone with a special patch. The sensor communicates with an application on the mobile phone and analyzes the heart rate in real time for up to 14 days using artificial intelligence. The results can easily be shared with a GP or cardiologist in real time. The ECG247 is already used by many general practitioners and cardiologists in Norway.

Dr Sandberg says that many people suffer from heart rhythm disturbances without knowing it. Atrial fibrillation is the most common heart rhythm disorder and is associated with an increased risk of stroke, heart failure, dementia, and premature death, for example. There are good preventative drugs if the disease is caught in time. International guidelines recommend that anyone at increased risk, i.e. anyone over 75 years of age and anyone over 65 with other illnesses (diabetes, high blood pressure, heart failure, history of (stroke or other cardiovascular disease) is regularly tested for the heart. fibrillation. Some younger people at high risk should also be tested.

“After more than 4 years of development work, we are proud that the ECG247 is now medically certified in Europe and FDA approval is pending. The study confirms that the ECG247 is reliable, precise and easy to use “, said the CEO of Appsens AS, Tord Ytterdahl. “We hope the study can contribute to a wider international launch of ECG247. By detecting cardiac arrhythmias at an early stage, ECG247 may help prevent serious complications such as stroke. many people who experience palpitations from time to time can now easily test themselves “.

Read more about ECG247 at and about the study here: Diagnostic accuracy and ease of use of the ECG247 smart cardiac sensor compared to conventional Holter technology (

About Appsens AS

Appsens is a medical technology company created in 2017. The company is headquartered in Lillesand, Norway and works closely with national health services and universities on the development of advanced medical equipment. Company employees have extensive knowledge of cardiology, wireless sensor technology and advanced software.

Contact: Tord Ytterdahl [email protected] com / / +4791369657

This information was brought to you by Cision,c3450964

The following files are available for download:


Lillian L. Pena